Por: The New York Times Health December 09, 2022
A key partner in Covax, the organization that has led the effort to bring Covid vaccines to poor and middle-income countries, will stop supplying the shots to a huge part of the global population in the year ahead, and provide them only to the lowest-income nations.The board of governors of Gavi, the nonprofit that supplies immunizations to developing countries, voted at a meeting in Geneva on Thursday to end Covax support for 37 countries,... + full article
The Boston Globe USA World December 08, 2022
The organization that has led the global effort to bring COVID vaccines to poor and middle-income countries will decide this week whether to shut down that project, ending a historic attempt to achieve global health equity with a tacit acknowledgment that the effort fell far... + más
States, not CDC, set school vaccination requirements | Los Angeles Times
Global Partners May End Broad Covid Vaccination Effort in Developing Countries | The New York Times
The New York Times USA Health December 07, 2022
The organization that has led the global effort to bring Covid vaccines to poor and middle-income countries will decide this week whether to shut down that project, ending a historic attempt to achieve global health equity with a tacit acknowledgment that the effort fell far... + más
Global partners may end broad COVID vaccination effort in developing countries | The Boston Globe
The New York Times USA Opinion December 07, 2022
Vaccines can end pandemics. That’s why they are central to any plan to prepare for the next one.Developing countries are attuned to this need after many waited nearly a year for ample Covid-19 vaccine supplies as wealthy countries enjoyed an extended period of first dibs.... + más
Justice Alito accused of being SCOTUS leaker after new report: Disgrace | Newsweek
Why would Mac Jones get a second opinion on his injury, and how common is that? | The Boston Globe
ABC News USA Health November 08, 2022
BERLIN -- BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, reported that its earnings in the third quarter were close to half what they were a year earlier, but the German pharmaceutical company still raised its expectations for vaccine revenue after... + más
Cancer vaccine may be ready by 2030, say founders of COVID vaccine makers BioNTech | ABC News
In Boston visit, BioNTech’s leaders say the pandemic isn’t close to being over | The Boston Globe
Associated Press USA Health November 07, 2022
BERLIN (AP) — BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, reported that its earnings in the third quarter were close to half what they were a year earlier, but the German pharmaceutical company still raised its expectations for after rolling out... + más
BioNTech earnings drop but forecast for vaccine income grows | ABC News
Politico USA Health October 15, 2022
Biden administration officials are raising concerns that the slow pace of developing a nasal vaccine for Covid-19 in the U.S. could pose a security risk as China, Iran and Russia approve their own vaccines taken through the nose or mouth. Though nasal and oral vaccines are being... + más
Nasal COVID vaccine blows clinical trial, flinging researchers back to the lab | Ars Technica
Nasal COVID vaccine fails to offer desired protection in testing | The Hill
The Hill USA Politics September 24, 2022
The U.S. and Pfizer will be lowering their number of global vaccine donations in response to a “reduced demand,” though the company says it is still committed to supplying the roughly 1 billion doses that the U.S. has committed to providing. Last year, the Biden... + más
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |